Assessment of eligibility criteria in renal cell carcinoma trials evaluating systemic therapy
Castro D, Prajapati S, Feng M, Chan E, Lee K, Paul T, Sehgal I, Patel J, Li X, Zengin Z, Ebrahimi H, Govindarajan A, Meza L, Mercier B, Chawla N, Dizman N, Philip E, Hsu J, Bergerot C, Chehrazi‐Raffle A, Rock A, Liu S, Tripathi A, Dorff T, Pal S. Assessment of eligibility criteria in renal cell carcinoma trials evaluating systemic therapy. BJU International 2023, 133: 297-304. PMID: 37548533, DOI: 10.1111/bju.16148.Peer-Reviewed Original ResearchHBV/HCV infectionExclusion of patientsHepatitis B virusConcurrent malignancyBrain metastasesEligibility criteriaHCV infectionSystemic therapyRCC trialsVirus infectionExact testHepatitis C virus infectionHuman immunodeficiency virus (HIV) infectionC virus infectionImmunodeficiency virus infectionFisher's exact testRestrictive eligibility criteriaContext of HIVChi-square testPrevalent comorbiditiesHIV infectionImmunotherapy trialsPatient populationB virusTrial characteristics